Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:06:01 ON 19 JUL 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:06:15 ON 19 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUL 2005 HIGHEST RN 855596-49-5
DICTIONARY FILE UPDATES: 17 JUL 2005 HIGHEST RN 855596-49-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10691770.str



chain nodes :
17 18 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
1-13 5-17 17-18 17-21 18-19 18-20
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
1-13 5-6 5-9 5-17 6-7 8-9 10-11 10-15 11-12 12-13 13-14 14-15 17-18 17-21 18-19 18-20
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 : 10 :

G1:O,CH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:06:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      4 TO ITERATE

100.0% PROCESSED         4 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            4 TO      200
PROJECTED ANSWERS:               2 TO      124

L2             2 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 09:06:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    119 TO ITERATE

100.0% PROCESSED       119 ITERATIONS                                37 ANSWERS
SEARCH TIME: 00.00.01

L3            37 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             161.33     161.54
```

FILE 'CAPLUS' ENTERED AT 09:06:43 ON 19 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Jul 2005 VOL 143 ISS 4
FILE LAST UPDATED: 18 Jul 2005 (20050718/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1036709 CAPLUS
DOCUMENT NUMBER: 142:23294
TITLE: Preparation of 7-morpholinobenzothiazol-2-ylureas for treatment of diseases related to the adenosine A2A receptor.
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242576	A1	20041202	US 2004-854059	20040526
WO 2004105755	A1	20041209	WO 2004-EP5474	20040521

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG
PRIORITY APPLN. INFO.: EP 2003-12118 A 20030530
OTHER SOURCE(S): MARPAT 142:23294
GI



I

AB Title compds. (I; R1 = cyclopentyl, trifluoromethylcyclopentyl, alkylcyclopentyl, cyclohexyl, alkylcyclohexyl, trifluoromethylcyclohexyl, alkoxyalkyl, bicycloheptyl, adamantyl, etc.; R2 = alkyl; R1R2N = oxaazabicyclooctyl), were prepared Thus, reaction of 4-methoxy-7-morpholinobenzothiazol-2-ylamine with Ph chloroformate and then with (-)-(exo)-methyl-(7-oxabicyclo[2.2.1]hept-2-yl)amine gave (exo)-(+)-3-(4-methoxy-7-morpholinylbenzothiazol-2-yl)-1-methyl-1-(7-oxabicyclo[2.2.1]hept-2-yl)urea. The latter bound to adenosine A2A receptors with pKi = 8.5.

IT **800386-24-7P 800386-25-8P 800386-26-9P**
800386-27-0P 800386-28-1P 800386-29-2P
800386-30-5P 800386-31-6P 800386-32-7P
800386-33-8P 800386-34-9P 800386-35-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of morpholinobenzothiazolylureas for treatment
of diseases related to the adenosine A2A receptor)

RN 800386-24-7 CAPLUS

CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-[4-(trifluoromethyl)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 800386-25-8 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(trans-4-methylcyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-26-9 CAPLUS
CN Urea, N-[trans-4-(hydroxymethyl)cyclohexyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-27-0 CAPLUS
CN Urea, N-[trans-4-(methoxymethyl)cyclohexyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-28-1 CAPLUS
CN Urea, N-[(1R,3S)-3-(hydroxymethyl)cyclopentyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-29-2 CAPLUS
CN Urea, N-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-30-5 CAPLUS

CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(1R,2S,4S)-7-oxabicyclo[2.2.1]hept-2-yl-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 800386-31-6 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(1R,2S,4S)-7-oxabicyclo[2.2.1]hept-2-yl-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 800386-32-7 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(1R,2S,4S)-7-oxabicyclo[2.2.1]hept-2-yl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-33-8 CAPLUS
CN Urea, N-[(1R,2S,4R,5S)-5-hydroxybicyclo[2.2.1]hept-2-yl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-34-9 CAPLUS
CN Urea, N-[(1R,2R,4R,5S)-5-hydroxybicyclo[2.2.1]hept-2-yl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-35-0 CAPLUS

CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:472390 CAPLUS
DOCUMENT NUMBER: 139:53026
TITLE: Preparation of ureidobenzothiazoles as adenosine receptor ligands.
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049741	A1	20030619	WO 2002-EP13761	20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003149036	A1	20030807	US 2002-308338	20021203
US 6727247	B2	20040427		
CA 2469596	AA	20030619	CA 2002-2469596	20021205
BR 2002014825	A	20040914	BR 2002-14825	20021205
EP 1455792	A1	20040915	EP 2002-804578	20021205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516006	T2	20050602	JP 2003-550790	20021205
US 2004229893	A1	20041118	US 2003-691770	20031023

PRIORITY APPLN. INFO.:
EP 2001-129228 A 20011210
US 2002-308338 A3 20021203
WO 2002-EP13761 W 20021205

OTHER SOURCE(S): MARPAT 139:53026

GI



I

AB Title compds. [I; R = alkoxy, halo; R1, R2 = H, alkyl, cycloalkyl, tetrahydropyran-4-yl; R1R2N = (substituted) 2-oxa-5-azabicyclo[2.2.1]heptyl, 3-endo-hydroxy-8-azabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.2]octyl, 1-oxo-2,8-diazaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, 8-azaspiro[4.5]decyl, 1-oxa-8-azaspiro[4.5]decyl, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 8-oxa-3-azabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.2.1]octyl, piperazinyl, piperidin-1-yl; X = O, CH2; n = 0-4], were prepared Thus, 4-methoxy-7-morpholin-4-ylbenzothiazol-2-ylamine in CH2Cl2 was treated with pyridine and Ph chloroformate and the resulting solution stirred for 45 min at ambient temperature; (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane was added and the mixture stirred at ambient temperature for 15 min and at 40° for 2.5 h. to give (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-ylbenzothiazol-2-yl)amide. This bound to human A2a receptors with pKi = 8.5.

IT **546093-27-0P 546093-30-5P 546093-31-6P**
546093-32-7P 546093-33-8P 546093-35-0P
546093-37-2P 546093-39-4P 546093-40-7P
546093-41-8P 546093-42-9P 546093-52-1P
546093-54-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureidobenzothiazoles as adenosine receptor ligands)

RN 546093-27-0 CAPLUS

CN Urea, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 546093-30-5 CAPLUS
CN Urea, N-cyclohexyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 546093-31-6 CAPLUS
CN Urea, N-(cis-4-fluorocyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-32-7 CAPLUS
CN Urea, N-(cis-4-methoxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-33-8 CAPLUS
CN Urea, N-(trans-4-hydroxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-35-0 CAPLUS
CN Urea, N-(cis-4-hydroxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-37-2 CAPLUS
CN Urea, N-(trans-4-methoxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-

benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-39-4 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 546093-40-7 CAPLUS
CN Urea, N-cycloheptyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 546093-41-8 CAPLUS
CN Urea, N-cyclopentyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 546093-42-9 CAPLUS
CN Urea, N-cyclopentyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-52-1 CAPLUS
CN Urea, N-[4-chloro-7-(1-piperidinyl)-2-benzothiazolyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 546093-54-3 CAPLUS
CN Urea, N-(4,4-difluorocyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:935384 CAPLUS
DOCUMENT NUMBER: 136:69803
TITLE: Preparation of N-benzothiazol-2-yl amides having affinity toward the A2A adenosine receptor
INVENTOR(S): Alanine, Alexander; Flohr, Alexander; Miller, Aubry Kern; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097786	A2	20011227	WO 2001-EP6506	20010608
WO 2001097786	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413086	AA	20011227	CA 2001-2413086	20010608
EP 1303272	A2	20030423	EP 2001-960284	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012395	A	20030708	BR 2001-12395	20010608
JP 2003535887	T2	20031202	JP 2002-503263	20010608
RU 2251419	C2	20050510	RU 2003-100518	20010608
NZ 522928	A	20050527	NZ 2001-522928	20010608
US 2002045615	A1	20020418	US 2001-881252	20010614
US 6521754	B2	20030218		
ZA 2002009730	A	20040301	ZA 2002-9730	20021129
US 2003125318	A1	20030703	US 2002-310508	20021205
US 6835732	B2	20041228		
NO 2002005978	A	20021212	NO 2002-5978	20021212

US 2003176695	A1	20030918	US 2002-322272		20021218
US 2005026906	A1	20050203	US 2004-930361		20040830
PRIORITY APPLN. INFO.:			EP 2000-113219	A	20000621
			WO 2001-EP6506	W	20010608
			US 2001-881252	A3	20010614
			US 2002-322272	A3	20021218

OTHER SOURCE(S): MARPAT 136:69803

GI



I

AB The title compds. [I; R1 = H, alkyl, alkoxy, etc.; R2, R3 = H, halo, alkyl, alkoxy; R4 = H, alkyl, alkenyl, etc.; R = (un)substituted Ph, (CH2)n(5-6 membered (non)aromatic heterocyclyl, (CH2)n+1Ph, etc.; n = 0-4; X = O, S, H2)], useful for the treatment of diseases related to the adenosine receptor, were prepared Thus, reacting 2-amino-4-methoxy-7-phenylbenzothiazole with benzoyl chloride in pyridine afforded 69% I [R1 = OMe; R2, R3 = H; R4 = Ph; R = Ph; X = O]. Biol. data for compds. I were given.

IT **383866-33-9P**, 3-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-1-methyl-1-((6-methylpyridin-3-yl)methyl)urea **383868-85-7P**, N-(2-Methoxyethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methylurea **383869-17-8P**, N'-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-(4-methoxyphenyl)-N-methylurea **383869-23-6P**, N'-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methyl-N-phenylurea **383869-78-1P**, (4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea **383869-86-1P**, N-Benzyl-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methylurea **383869-88-3P**, N'-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methyl-N-phenethylurea **383870-02-8P**, N-Benzyl-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea **383870-05-1P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N'-phenethylurea **383870-07-3P**, N-(2-Methoxyethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea **383870-09-5P**, N-(2-Dimethylaminoethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methylurea **383870-11-9P**, N-(2-Dimethylaminoethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383866-33-9 CAPLUS

CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-[(6-methyl-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-85-7 CAPLUS
CN Urea, N-(2-methoxyethyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 383869-17-8 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 383869-23-6 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 383869-78-1 CAPLUS
CN Urea, [4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-86-1 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 383869-88-3 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 383870-02-8 CAPLUS
CN Urea, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N'-(phenylmethyl)-
(9CI) (CA INDEX NAME)



RN 383870-05-1 CAPLUS
CN Urea, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N'-(2-phenylethyl)-
(9CI) (CA INDEX NAME)



RN 383870-07-3 CAPLUS
CN Urea, N-(2-methoxyethyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-
(9CI) (CA INDEX NAME)



RN 383870-09-5 CAPLUS
CN Urea, N-[2-(dimethylamino)ethyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 383870-11-9 CAPLUS
CN Urea, N-[2-(dimethylamino)ethyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.62	178.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -2.19 -2.19

FILE 'REGISTRY' ENTERED AT 09:08:56 ON 19 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUL 2005 HIGHEST RN 855596-49-5
DICTIONARY FILE UPDATES: 17 JUL 2005 HIGHEST RN 855596-49-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10691770astr.str



chain nodes :
17 18 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
1-13 5-17 17-18 17-20
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-13 5-6 5-9 5-17 6-7 8-9 10-11 10-15 11-12 12-13 13-14 14-15 17-18
17-20
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 : 10 :

G1:O,CH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 20:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 09:09:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     19 TO ITERATE

100.0% PROCESSED       19 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          119 TO      641
PROJECTED ANSWERS:               0 TO        0

L6             0 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 09:09:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    474 TO ITERATE

100.0% PROCESSED      474 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

L7             4 SEA SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\10691770bstr.str
```




```
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15
chain bonds :
1-13
ring bonds :
1-2  1-7  2-3  3-4  4-8  5-6  5-9  6-7  7-8  8-9  10-11  10-15  11-12  12-13  13-14
 14-15
exact/norm bonds :
1-13  5-6  5-9  6-7  8-9  10-11  10-15  11-12  12-13  13-14  14-15
normalized bonds :
1-2  1-7  2-3  3-4  4-8  7-8
isolated ring systems :
containing 1 : 10 :
```

G1:O,CH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s l8
SAMPLE SEARCH INITIATED 09:10:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 74 TO ITERATE

100.0% PROCESSED 74 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 964 TO 1996
PROJECTED ANSWERS: 186 TO 772

L9 24 SEA SSS SAM L8

=> s l8 sss full

FULL SEARCH INITIATED 09:10:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1389 TO ITERATE

100.0% PROCESSED 1389 ITERATIONS 483 ANSWERS
SEARCH TIME: 00.00.01

L10 483 SEA SSS FUL L8

=> d his

(FILE 'HOME' ENTERED AT 09:06:01 ON 19 JUL 2005)

FILE 'REGISTRY' ENTERED AT 09:06:15 ON 19 JUL 2005
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 37 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:06:43 ON 19 JUL 2005
L4 3 S L3

FILE 'REGISTRY' ENTERED AT 09:08:56 ON 19 JUL 2005
L5 STRUCTURE UPLOADED
L6 0 S L5
L7 4 S L5 SSS FULL
L8 STRUCTURE UPLOADED
L9 24 S L8
L10 483 S L8 SSS FULL

=> s l7
SAMPLE SEARCH INITIATED 09:11:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 119 TO 641
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L5

=> FIL CAPLUS
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	323.52	501.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.19

FILE 'CAPLUS' ENTERED AT 09:11:18 ON 19 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jul 2005 VOL 143 ISS 4
FILE LAST UPDATED: 18 Jul 2005 (20050718/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l7
L12             6 L7

=> s l10
L13            16 L10

=> s l13 and thu
           142 THU
       2249064 THUS
       2249191 THU
                 (THU OR THUS)
L14            8 L13 AND THU

=> d his

     (FILE 'HOME' ENTERED AT 09:06:01 ON 19 JUL 2005)

     FILE 'REGISTRY' ENTERED AT 09:06:15 ON 19 JUL 2005
L1                STRUCTURE UPLOADED
L2              2 S L1
L3             37 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:06:43 ON 19 JUL 2005
L4              3 S L3

     FILE 'REGISTRY' ENTERED AT 09:08:56 ON 19 JUL 2005
L5                STRUCTURE UPLOADED
L6              0 S L5
L7              4 S L5 SSS FULL
L8                STRUCTURE UPLOADED
L9             24 S L8
L10           483 S L8 SSS FULL
L11             0 S L7

     FILE 'CAPLUS' ENTERED AT 09:11:18 ON 19 JUL 2005
L12             6 S L7
L13            16 S L10
L14             8 S L13 AND THU

=> d l12 ibib abs hitstr tot

L12  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:1036709  CAPLUS
```

DOCUMENT NUMBER: 142:23294
TITLE: Preparation of 7-morpholinobenzothiazol-2-ylureas for treatment of diseases related to the adenosine A2A receptor.
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242576	A1	20041202	US 2004-854059	20040526
WO 2004105755	A1	20041209	WO 2004-EP5474	20040521

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-12118 A 20030530
OTHER SOURCE(S): MARPAT 142:23294
GI



I

AB Title compds. (I; R1 = cyclopentyl, trifluoromethylcyclopentyl, alkylcyclopentyl, cyclohexyl, alkylcyclohexyl, trifluoromethylcyclohexyl, alkoxyalkyl, bicycloheptyl, adamantyl, etc.; R2 = alkyl; R1R2N = oxaazabicyclooctyl), were prepared Thus, reaction of 4-methoxy-7-morpholinobenzothiazol-2-ylamine with Ph chloroformate and then with (-)-(exo)-methyl-(7-oxabicyclo[2.2.1]hept-2-yl)amine gave (exo)-(+)-3-(4-methoxy-7-morpholinylbenzothiazol-2-yl)-1-methyl-1-(7-oxabicyclo[2.2.1]hept-2-yl)urea. The latter bound to adenosine A2A receptors with pKi = 8.5.

IT **383865-57-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of morpholinobenzothiazolylureas for treatment of diseases related to the adenosine A2A receptor)
RN 383865-57-4 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1019774 CAPLUS
DOCUMENT NUMBER: 142:6545
TITLE: Preparation of benzothiazoles as A2a receptor ligands for the treatment of Alzheimer's disease
INVENTOR(S): Flohr, Alexander; Jakob-roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004235842	A1	20041125	US 2004-848436	20040518
WO 2004103367	A1	20041202	WO 2004-EP5179	20040514

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-11090 A 20030521
GI



I



II



III

AB Title compds. I [R = cyclopentyl, cyclohexyl, Et, etc.; X = CH, N] and their pharmaceutically acceptable salts and formulations were prepared For example, sequential condensation of amine II, e.g., prepared from 4-bromo-2-nitroanisole in 6-steps, Ph chloroformate and (trans)-cyclohexane-1,4-diol afforded carbamic acid III in 7% yield. The pKi of 13-examples of compds. I ranged from 7.6-8.7, with the most preferred compds. having a pKi >8.0. Of note, compds. I possess a high affinity towards the A2a receptor (no data provided). Compds. I are claimed useful for the treatment of Alzheimer's disease, depression, Parkinson's disease and ADHD.

IT **383865-57-4**, 4-Methoxy-7-morpholin-4-ylbenzothiazol-2-ylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzothiazoles as A2a receptor ligands for the treatment of Alzheimer's disease)

RN 383865-57-4 CAPLUS

CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:569886 CAPLUS
DOCUMENT NUMBER: 141:123657
TITLE: Cyclization process for substituted benzothiazole derivatives
INVENTOR(S): Spurr, Paul
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004138465	A1	20040715	US 2003-743613	20031222
WO 2004060879	A2	20040722	WO 2003-EP14928	20031229
WO 2004060879	A3	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-48 A 20030107
OTHER SOURCE(S): CASREACT 141:123657; MARPAT 141:123657
GI



I



II

AB The present invention relates to a process for preparation of amino substituted benzothiazole derivs. of formula (I) [wherein R1, R2, R3 = H, lower alkyl, lower alkoxy, halogen; R4 = H, lower alkyl, lower alkyloxy, halogen, five or six membered non aromatic heterocyclyl group unsubstituted or substituted by lower alkyl or an oxo-group, NR5R6 (wherein R5, R5 = H, lower alkyl, -C(O)-lower alkyl, -(CH2)nO-lower alkyl or benzyl, optionally substituted by lower alkyl, or NR5R6 is an five or six membered heteroaryl group); R1 and R2 or R2 and R3 may form together with the corresponding carbon atoms a ring containing -OCH2O- or -CH:CH-CH:CH-; R = H or -C(O)R' (wherein R' = a five or six membered non aromatic heterocyclyl group, five or six membered heteroaryl group or is aryl, which rings may be substituted by the groups selected from lower alkyl, halogen-lower alkyl, lower alkoxy, cyano, nitro, CHO, CO2H or by pyrrolidin-1-ylmethyl; n = 1-4)] or a

pharmaceutically acceptable salt thereof, wherein the cyclization is carried out by the treatment of a N-phenylthiourea or N-phenyl-N'-acylthiourea derivs. of formula (II; R-R4 = same as above) with sulfoxide/HBr/solvent to give the desired products of formula I [R = H, C(O)R']. Thus, to a suspension of 15.0 g (43.7 mmol) N-[3-(3-benzoylthioureido)-4-methoxyphenyl]acetamide in 200 mL glacial acetic acid was added 7.65 mL (43.6 mmol) a 5.7 M solution of HBr in acetic acid, and the mixture was heated at 90° for 1 h. DMSO (2.5 mL, 48.0 mmol) was then added and the mixture was heated at 90° for 1.5 h, cooled to room temperature, and poured onto 1000 mL distilled water, stirred for 15 min, and then filtered, followed by washing the filter cake with water and then drying in vacuo at 50° to give 12.8 g (86%) N-(7-acetylamino-4-methoxybenzothiazol-2-yl)benzamide as a light brown solid.

IT **383865-57-4P**, [4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted benzothiazole derivs. by cyclization of N-phenylthiourea or N-phenyl-N'-acylthiourea derivs.)

RN 383865-57-4 CAPLUS

CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:472390 CAPLUS
DOCUMENT NUMBER: 139:53026
TITLE: Preparation of ureidobenzothiazoles as adenosine receptor ligands.
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049741	A1	20030619	WO 2002-EP13761	20021205

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003149036	A1	20030807	US 2002-308338	20021203
US 6727247	B2	20040427		
CA 2469596	AA	20030619	CA 2002-2469596	20021205
BR 2002014825	A	20040914	BR 2002-14825	20021205
EP 1455792	A1	20040915	EP 2002-804578	20021205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516006	T2	20050602	JP 2003-550790	20021205
US 2004229893	A1	20041118	US 2003-691770	20031023
PRIORITY APPLN. INFO.:			EP 2001-129228 A	20011210
			US 2002-308338 A3	20021203
			WO 2002-EP13761 W	20021205

OTHER SOURCE(S): MARPAT 139:53026

GI



I

AB Title compds. [I; R = alkoxy, halo; R1, R2 = H, alkyl, cycloalkyl, tetrahydropyran-4-yl; R1R2N = (substituted) 2-oxa-5-azabicyclo[2.2.1]heptyl, 3-endo-hydroxy-8-azabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.2]octyl, 1-oxo-2,8-diazaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, 8-azaspiro[4.5]decyl, 1-oxa-8-azaspiro[4.5]decyl, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 8-oxa-3-azabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.2.1]octyl, piperazinyl, piperidin-1-yl; X = O, CH2; n = 0-4], were prepared Thus, 4-methoxy-7-morpholin-4-ylbenzothiazol-2-ylamine in CH2Cl2 was treated with pyridine and Ph chloroformate and the resulting solution stirred for 45 min at ambient temperature; (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane was added and the mixture stirred at ambient temperature for 15 min and at 40° for 2.5 h. to give (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-ylbenzothiazol-2-yl)amide. This bound to human A2a receptors with pKi = 8.5.

IT **383865-57-4**, 4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylamine
383869-46-3, 4-Methoxy-7-piperidin-1-ylbenzothiazol-2-ylamine
546093-47-4, 4-Chloro-7-(piperidin-1-yl)benzothiazol-2-ylamine

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ureidobenzothiazoles as adenosine receptor ligands)
RN 383865-57-4 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 383869-46-3 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 546093-47-4 CAPLUS
CN 2-Benzothiazolamine, 4-chloro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:417626 CAPLUS
DOCUMENT NUMBER: 139:6865
TITLE: Nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands

INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043636	A1	20030530	WO 2002-EP12562	20021111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003134854	A1	20030717	US 2002-288100	20021105
US 6620811	B2	20030916		
CA 2467552	AA	20030530	CA 2002-2467552	20021111
EP 1448198	A1	20040825	EP 2002-787632	20021111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014245	A	20041214	BR 2002-14245	20021111
PRIORITY APPLN. INFO.:			EP 2001-127312 A	20011119
			WO 2002-EP12562 W	20021111

OTHER SOURCE(S): MARPAT 139:6865
GI



I

AB Title compds. I [R = 2-substituted 4-pyridyl, 4-substituted 3-pyridyl; R1 = Ph, piperidin-1-yl, morpholinyl] were prepared for use as adenosine A2A receptor ligands. Thus, 4-methoxy-7-morpholinobenzothiazole-2-amine was acylated with 2-chloroisonicotinoyl chloride and treated with HOCH2CH2OMe to give I [R = 2-(2-methoxyethoxy)pyridin-4-yl, R1 = morpholino] which had a pKi for the human A2A receptor of 8.50.

IT **383865-57-4 383869-46-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)

RN 383865-57-4 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 383869-46-3 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:935384 CAPLUS
DOCUMENT NUMBER: 136:69803
TITLE: Preparation of N-benzothiazol-2-yl amides having affinity toward the A2A adenosine receptor
INVENTOR(S): Alanine, Alexander; Flohr, Alexander; Miller, Aubry Kern; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097786	A2	20011227	WO 2001-EP6506	20010608
WO 2001097786	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2413086	AA	20011227	CA 2001-2413086	20010608
EP 1303272	A2	20030423	EP 2001-960284	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012395	A	20030708	BR 2001-12395	20010608
JP 2003535887	T2	20031202	JP 2002-503263	20010608
RU 2251419	C2	20050510	RU 2003-100518	20010608
NZ 522928	A	20050527	NZ 2001-522928	20010608
US 2002045615	A1	20020418	US 2001-881252	20010614
US 6521754	B2	20030218		
ZA 2002009730	A	20040301	ZA 2002-9730	20021129
US 2003125318	A1	20030703	US 2002-310508	20021205
US 6835732	B2	20041228		
NO 2002005978	A	20021212	NO 2002-5978	20021212
US 2003176695	A1	20030918	US 2002-322272	20021218
US 2005026906	A1	20050203	US 2004-930361	20040830

PRIORITY APPLN. INFO.:	EP 2000-113219	A 20000621
	WO 2001-EP6506	W 20010608
	US 2001-881252	A3 20010614
	US 2002-322272	A3 20021218

OTHER SOURCE(S): MARPAT 136:69803
GI



I

AB The title compds. [I; R1 = H, alkyl, alkoxy, etc.; R2, R3 = H, halo, alkyl, alkoxy; R4 = H, alkyl, alkenyl, etc.; R = (un)substituted Ph, (CH2)n(5-6 membered (non)aromatic heterocyclyl, (CH2)n+1Ph, etc.; n = 0-4; X = O, S, H2)], useful for the treatment of diseases related to the adenosine receptor, were prepared Thus, reacting 2-amino-4-methoxy-7-phenylbenzothiazole with benzoyl chloride in pyridine afforded 69% I [R1 = OMe; R2, R3 = H; R4 = Ph; R = Ph; X = O]. Biol. data for compds. I were given.

IT **383869-46-3**, 4-Methoxy-7-piperidin-1-yl-benzothiazol-2-ylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383869-46-3 CAPLUS

CN 2-Benzothiazolamine, 4-methoxy-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



IT **383865-57-4P**, 2-Amino-4-methoxy-7-(morpholin-4-yl)benzothiazole
383868-20-0P, 4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-ylamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)
RN 383865-57-4 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 383868-20-0 CAPLUS
CN 2-Benzothiazolamine, 7-(4-morpholinyl)-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



=> d l14 ibib abs hitstr tot

L14 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1036709 CAPLUS
DOCUMENT NUMBER: 142:23294
TITLE: Preparation of 7-morpholinobenzothiazol-2-ylureas for treatment of diseases related to the adenosine A2A receptor.
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242576	A1	20041202	US 2004-854059	20040526
WO 2004105755	A1	20041209	WO 2004-EP5474	20040521

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-12118 A 20030530
OTHER SOURCE(S): MARPAT 142:23294
GI



I

AB Title compds. (I; R1 = cyclopentyl, trifluoromethylcyclopentyl, alkylcyclopentyl, cyclohexyl, alkylcyclohexyl, trifluoromethylcyclohexyl, alkoxyalkyl, bicycloheptyl, adamantyl, etc.; R2 = alkyl; R1R2N = oxaazabicyclooctyl), were prepared **Thus**, reaction of 4-methoxy-7-morpholinobenzothiazol-2-ylamine with Ph chloroformate and then with (-)-(exo)-methyl-(7-oxabicyclo[2.2.1]hept-2-yl)amine gave (exo)-(+)-3-(4-methoxy-7-morpholinylbenzothiazol-2-yl)-1-methyl-1-(7-oxabicyclo[2.2.1]hept-2-yl)urea. The latter bound to adenosine A2A

receptors with pKi = 8.5.

IT **800386-24-7P 800386-25-8P 800386-26-9P**
800386-27-0P 800386-28-1P 800386-29-2P
800386-30-5P 800386-31-6P 800386-32-7P
800386-33-8P 800386-34-9P 800386-35-0P
800386-36-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of morpholinobenzothiazolylureas for treatment
of diseases related to the adenosine A2A receptor)

RN 800386-24-7 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-[4-(trifluoromethyl)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 800386-25-8 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(trans-4-methylcyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-26-9 CAPLUS
CN Urea, N-[trans-4-(hydroxymethyl)cyclohexyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-27-0 CAPLUS
CN Urea, N-[trans-4-(methoxymethyl)cyclohexyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-28-1 CAPLUS
CN Urea, N-[(1R,3S)-3-(hydroxymethyl)cyclopentyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-29-2 CAPLUS

CN Urea, N-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-30-5 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(1R,2S,4S)-7-oxabicyclo[2.2.1]hept-2-yl-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 800386-31-6 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(1R,2S,4S)-7-oxabicyclo[2.2.1]hept-2-yl-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 800386-32-7 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(1R,2S,4S)-7-oxabicyclo[2.2.1]hept-2-yl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-33-8 CAPLUS
CN Urea, N-[(1R,2S,4R,5S)-5-hydroxybicyclo[2.2.1]hept-2-yl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-34-9 CAPLUS

CN Urea, N-[(1R,2R,4R,5S)-5-hydroxybicyclo[2.2.1]hept-2-yl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 800386-35-0 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 800386-36-1 CAPLUS
CN 8-Oxa-3-azabicyclo[3.2.1]octane-3-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT **383865-57-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of morpholinobenzothiazolylureas for treatment of diseases

related to the adenosine A2A receptor)
RN 383865-57-4 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:995771 CAPLUS
DOCUMENT NUMBER: 141:424179
TITLE: Imidazolyl benzothiazoles as adenosine receptor ligands, processes for their preparations, pharmaceutical formulations and uses thereof
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229862	A1	20041118	US 2004-843241	20040511
WO 2004101558	A1	20041125	WO 2004-EP4843	20040506

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-9842 A 20030513
OTHER SOURCE(S): MARPAT 141:424179
GI



I



II

AB Title compds. I [wherein R1 = Ph or N/O-heterocycle; R2 = (un)annulated imidazole, or pharmaceutically acceptable salts thereof] were prepared as adenosine receptor ligands. Also disclosed are the processes for the prepns. of I, pharmaceutical formulations comprising I, and use of I for the treatment of Alzheimer's disease, depression, Parkinson's disease and ADHD. **Thus**, coupling of imidazole-2-carboxylic acid with 2-methoxy-5-(morpholin-4-yl)phenylamine (9%), followed by treatment with Lawesson reagent (59%), and subsequent cyclization in the presence of potassium hexacyanoferrate (47%) gave compound II. I were measured to have a good affinity to human adenosine A2A receptor and human adenosine A1 receptor with pKi of 7.0-9.3 and 5.1-57, resp.

IT **538327-31-0P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxamide **538327-38-7P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid **538327-75-2P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid (2-oxo-2-phenylethyl)amide **538328-14-2P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid [2-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-2-oxoethyl]amide **538328-15-3P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid [2-(3-methylbenzo[b]thiophen-2-yl)-2-oxoethyl]amide **538328-19-7P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid [2-oxo-2-(thiophen-2-yl)ethyl]amide **538328-20-0P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid [2-oxo-2-(thiophen-3-yl)ethyl]amide **796061-94-4P**, 1-[3-Methoxymethyl-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3H-imidazo[4,5-b]pyridin-5-yl]piperidin-4-ol **796061-96-6P**, [3-Methoxymethyl-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3H-imidazo[4,5-b]pyridin-5-yl](methyl)[(tetrahydropyran-4-yl)methyl]amine **796062-00-5P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid [2-(benzo[b]thiophen-3-yl)-2-oxoethyl]amide **796062-08-3P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid [2-oxo-3-(thiophen-2-yl)propyl]amide **796062-10-7P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carboxylic acid (2-oxocyclohexyl)amide **796062-12-9P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carbonitrile **796062-13-0P**, 4-Methoxy-7-(morpholin-4-yl)benzothiazole-2-carbothioic acid amide **796062-18-5P**, 4-Hydroxy-5-[[[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]carbonyl]amino]azepane-1-carboxylic acid tert-butyl ester **796062-19-6P**, 4-[[[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]carbonyl]amino]-5-oxoazepane-1-carboxylic acid tert-butyl ester **796062-32-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of imidazolyl benzothiazoles as adenosine receptor ligands)

RN 538327-31-0 CAPLUS
CN 2-Benzothiazolecarboxamide, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 538327-38-7 CAPLUS
CN 2-Benzothiazolecarboxylic acid, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 538327-75-2 CAPLUS
CN 2-Benzothiazolecarboxamide, 4-methoxy-7-(4-morpholinyl)-N-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 538328-14-2 CAPLUS
CN 2-Benzothiazolecarboxamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 538328-15-3 CAPLUS
CN 2-Benzothiazolecarboxamide, 4-methoxy-N-[2-(3-methylbenzo[b]thien-2-yl)-2-oxoethyl]-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 538328-19-7 CAPLUS
CN 2-Benzothiazolecarboxamide, 4-methoxy-7-(4-morpholinyl)-N-[2-oxo-2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 538328-20-0 CAPLUS
CN 2-Benzothiazolecarboxamide, 4-methoxy-7-(4-morpholinyl)-N-[2-oxo-2-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 796061-94-4 CAPLUS
CN 4-Piperidinol, 1-[3-(methoxymethyl)-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3H-imidazo[4,5-b]pyridin-5-yl]- (9CI) (CA INDEX NAME)



RN 796061-96-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-5-amine, 3-(methoxymethyl)-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796062-00-5 CAPLUS
CN 2-Benzothiazolecarboxamide, N-(2-benzo[b]thien-3-yl-2-oxoethyl)-4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796062-08-3 CAPLUS
CN 2-Benzothiazolecarboxamide, 4-methoxy-7-(4-morpholinyl)-N-[2-oxo-3-(2-thienyl)propyl]- (9CI) (CA INDEX NAME)



RN 796062-10-7 CAPLUS
CN 2-Benzothiazolecarboxamide, 4-methoxy-7-(4-morpholinyl)-N-(2-oxocyclohexyl)- (9CI) (CA INDEX NAME)



RN 796062-12-9 CAPLUS
CN 2-Benzothiazolecarbonitrile, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796062-13-0 CAPLUS
CN 2-Benzothiazolecarbothioamide, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796062-18-5 CAPLUS
CN 1H-Azepine-1-carboxylic acid, hexahydro-4-hydroxy-5-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 796062-19-6 CAPLUS
CN 1H-Azepine-1-carboxylic acid, hexahydro-4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 796062-32-3 CAPLUS
CN 2-Benzothiazolecarboximidothioic acid, 4-methoxy-7-(4-morpholinyl)-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

IT **796061-73-9P**, 2-(1H-Benzimidazol-2-yl)-4-methoxy-7-(morpholin-4-yl)benzothiazole **796061-84-2P**, 5-Chloro-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3H-imidazo[4,5-b]pyridine **796061-87-5P**, 5-Chloro-3-(methoxymethyl)-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3H-imidazo[4,5-b]pyridine **796061-88-6P**, 3-Methoxymethyl-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-5-(morpholin-4-yl)-3H-imidazo[4,5-b]pyridine **796062-14-1P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepine-6-carboxylic acid tert-butyl ester **796062-20-9P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine hydrochloride **796062-27-6P**, 2-Methoxy-1-[2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]ethanone **796062-31-2P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester **796062-34-5P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine hydrochloride **796062-38-9P**, (2-Chloromethylpyridin-4-yl)[2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]methanone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(ligand; preparation of imidazolyl benzothiazoles as adenosine receptor ligands)

RN 796061-73-9 CAPLUS

CN Benzothiazole, 2-(1H-benzimidazol-2-yl)-4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796061-84-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 5-chloro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796061-87-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-chloro-3-(methoxymethyl)-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796061-88-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 3-(methoxymethyl)-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796062-14-1 CAPLUS
CN Imidazo[4,5-d]azepine-6(1H)-carboxylic acid, 4,5,7,8-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 796062-20-9 CAPLUS
CN Imidazo[4,5-d]azepine, 1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 796062-27-6 CAPLUS
CN Imidazo[4,5-d]azepine, 1,4,5,6,7,8-hexahydro-6-(methoxyacetyl)-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-31-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 796062-34-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 796062-38-9 CAPLUS
CN Imidazo[4,5-d]azepine, 6-[[2-(chloromethyl)-4-pyridinyl]carbonyl]-1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-

(9CI) (CA INDEX NAME)



IT **796061-70-6P**, 2-(1H-Imidazol-2-yl)-4-methoxy-7-(morpholin-4-yl)benzothiazole **796061-76-2P**, 4-Methoxy-2-(1-methyl-1H-benzimidazol-2-yl)-7-(morpholin-4-yl)benzothiazole **796061-81-9P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-5-methyl-3H-imidazo[4,5-b]pyridine **796061-89-7P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-5-(morpholin-4-yl)-3H-imidazo[4,5-b]pyridine **796061-90-0P**, 3-Methoxymethyl-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-5-(pyrrolidin-1-yl)-3H-imidazo[4,5-b]pyridine **796061-91-1P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-5-(pyrrolidin-1-yl)-3H-imidazo[4,5-b]pyridine **796061-92-2P**, [2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3H-imidazo[4,5-b]pyridin-5-yl]dimethylamine **796061-93-3P**, 1-[2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3H-imidazo[4,5-b]pyridin-5-yl]piperidin-4-ol **796061-95-5P**, [2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3H-imidazo[4,5-b]pyridin-5-yl](methyl)[(tetrahydropyran-4-yl)methyl]amine **796061-97-7P**, 4-Methoxy-7-(morpholin-4-yl)-2-(4-phenyl-1H-imidazol-2-yl)benzothiazole **796061-98-8P**, 2-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1H-imidazol-2-yl]-4-methoxy-7-(morpholin-4-yl)benzothiazole **796061-99-9P**, 2-[5-(Benzo[b]thiophen-3-yl)-1H-imidazol-2-yl]-4-methoxy-7-(morpholin-4-yl)benzothiazole **796062-01-6P**, 4-Methoxy-7-(morpholin-4-yl)-2-[4-(thiophen-2-yl)-1H-imidazol-2-yl]benzothiazole **796062-02-7P**, 4-Methoxy-7-(morpholin-4-yl)-2-[4-(thiophen-3-yl)-1H-imidazol-2-yl]benzothiazole **796062-03-8P**, 4-Methoxy-2-[5-(3-methylbenzo[b]thiophen-2-yl)-1H-imidazol-2-yl]-7-(morpholin-4-yl)benzothiazole **796062-05-0P**, 4-Methoxy-7-(morpholin-4-yl)-2-[4-[(thiophen-2-yl)methyl]-1H-imidazol-2-yl]benzothiazole **796062-09-4P**, 4-Methoxy-7-(morpholin-4-yl)-2-(4,5,6,7-tetrahydro-1H-benzimidazol-2-yl)benzothiazole **796062-11-8P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-3,4,6,7-tetrahydropyrano[3,4-d]imidazole **796062-21-0P**, (4-Fluorophenyl)[2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]methanone **796062-22-1P**, 1-[2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]ethanone **796062-23-2P**, [2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl][2-methylphenyl]methanone **796062-24-3P**, 1-[2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]-2,2-dimethylpropan-1-one **796062-25-4P**, Cyclopropyl[2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]methanone **796062-26-5P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepine-6-

carboxylic acid dimethylamide **796062-28-7P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepine-6-carboxylic acid ethyl ester **796062-29-8P**, 6-Methylsulfonyl-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine **796062-30-1P**, 6-(2-Methoxyethyl)-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine **796062-35-6P**, [2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl](2-methylphenyl)methanone **796062-36-7P**, 1-[2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone **796062-37-8P**, 2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylic acid ethyl ester **796062-40-3P**, [2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl][2-[(pyrrolidin-1-yl)methyl]pyridin-4-yl]methanone **796062-41-4P**, [2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]-(2-methylpyridin-4-yl)methanone **796062-42-5P**, 5-Benzyl-2-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine **796062-46-9P**, 2-[2-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ligand; preparation of imidazolyl benzothiazoles as adenosine receptor ligands)

RN 796061-70-6 CAPLUS
CN Benzothiazole, 2-(1H-imidazol-2-yl)-4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796061-76-2 CAPLUS
CN Benzothiazole, 4-methoxy-2-(1-methyl-1H-benzimidazol-2-yl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796061-81-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 796061-89-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796061-90-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-(methoxymethyl)-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 796061-91-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridine, 2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 796061-92-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 796061-93-3 CAPLUS
CN 4-Piperidinol, 1-[2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-1H-imidazo[4,5-b]pyridin-5-yl]- (9CI) (CA INDEX NAME)



RN 796061-95-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796061-97-7 CAPLUS
CN Benzothiazole, 4-methoxy-7-(4-morpholinyl)-2-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 796061-98-8 CAPLUS
CN Benzothiazole, 2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-imidazol-2-yl]-4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796061-99-9 CAPLUS
CN Benzothiazole, 2-(4-benzo[b]thien-3-yl-1H-imidazol-2-yl)-4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796062-01-6 CAPLUS
CN Benzothiazole, 4-methoxy-7-(4-morpholinyl)-2-[4-(2-thienyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 796062-02-7 CAPLUS
CN Benzothiazole, 4-methoxy-7-(4-morpholinyl)-2-[4-(3-thienyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 796062-03-8 CAPLUS
CN Benzothiazole, 4-methoxy-2-[4-(3-methylbenzo[b]thien-2-yl)-1H-imidazol-2-yl]-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 796062-05-0 CAPLUS
CN Benzothiazole, 4-methoxy-7-(4-morpholinyl)-2-[4-(2-thienylmethyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 796062-09-4 CAPLUS
CN Benzothiazole, 4-methoxy-7-(4-morpholinyl)-2-(4,5,6,7-tetrahydro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 796062-11-8 CAPLUS
CN Pyrano[3,4-d]imidazole, 1,4,6,7-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-21-0 CAPLUS
CN Imidazo[4,5-d]azepine, 6-(4-fluorobenzoyl)-1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-22-1 CAPLUS
CN Imidazo[4,5-d]azepine, 6-acetyl-1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-23-2 CAPLUS
CN Imidazo[4,5-d]azepine, 1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-(2-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 796062-24-3 CAPLUS
CN Imidazo[4,5-d]azepine, 6-(2,2-dimethyl-1-oxopropyl)-1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-25-4 CAPLUS
CN Imidazo[4,5-d]azepine, 6-(cyclopropylcarbonyl)-1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-26-5 CAPLUS
CN Imidazo[4,5-d]azepine-6(1H)-carboxamide, 4,5,7,8-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 796062-28-7 CAPLUS
CN Imidazo[4,5-d]azepine-6(1H)-carboxylic acid, 4,5,7,8-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 796062-29-8 CAPLUS
CN Imidazo[4,5-d]azepine, 1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 796062-30-1 CAPLUS
CN Imidazo[4,5-d]azepine, 1,4,5,6,7,8-hexahydro-6-(2-methoxyethyl)-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-35-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-(2-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 796062-36-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-acetyl-4,5,6,7-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 796062-37-8 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 796062-40-3 CAPLUS
CN Imidazo[4,5-d]azepine, 1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-[[2-(1-pyrrolidinylmethyl)-4-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 796062-41-4 CAPLUS
CN Imidazo[4,5-d]azepine, 1,4,5,6,7,8-hexahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-[(2-methyl-4-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 796062-42-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 796062-46-9 CAPLUS
CN Imidazo[4,5-d]azepine-6(1H)-acetamide, 4,5,7,8-tetrahydro-2-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:569886 CAPLUS
DOCUMENT NUMBER: 141:123657
TITLE: Cyclization process for substituted benzothiazole derivatives
INVENTOR(S): Spurr, Paul
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 13 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004138465	A1	20040715	US 2003-743613	20031222
WO 2004060879	A2	20040722	WO 2003-EP14928	20031229
WO 2004060879	A3	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-48 A 20030107
OTHER SOURCE(S): CASREACT 141:123657; MARPAT 141:123657
GI



I



II

AB The present invention relates to a process for preparation of amino substituted benzothiazole derivs. of formula (I) [wherein R1, R2, R3 = H, lower alkyl, lower alkoxy, halogen; R4 = H, lower alkyl, lower alkyloxy, halogen, five or six membered non aromatic heterocyclyl group unsubstituted or substituted by lower alkyl or an oxo-group, NR5R6 (wherein R5, R5 = H, lower alkyl, -C(O)-lower alkyl, -(CH2)nO-lower alkyl or benzyl, optionally substituted by lower alkyl, or NR5R6 is an five or six membered heteroaryl group); R1 and R2 or R2 and R3 may form together with the corresponding carbon atoms a ring containing -OCH2O- or -CH:CH-CH:CH-; R = H or -C(O)R' (wherein R' = a five or six membered non aromatic heterocyclyl group, five or six membered heteroaryl group or is aryl, which rings may be substituted by the groups selected from lower alkyl, halogen-lower alkyl, lower alkoxy, cyano, nitro, CHO, CO2H or by pyrrolidin-1-ylmethyl; n = 1-4)] or a pharmaceutically acceptable salt thereof, wherein the cyclization is carried out by the treatment of a N-phenylthiourea or N-phenyl-N'-acylthiourea derivs. of formula (II; R-R4 = same as above) with sulfoxide/HBr/solvent to give the desired products of formula I [R = H, C(O)R']. **Thus**, to a suspension of 15.0 g (43.7 mmol) N-[3-(3-benzoylthioureido)-4-methoxyphenyl]acetamide in 200 mL glacial acetic acid was added 7.65 mL (43.6 mmol) a 5.7 M solution of HBr in acetic acid, and the mixture was heated at 90° for 1 h. DMSO (2.5 mL, 48.0 mmol) was then added and the mixture was heated at 90° for 1.5 h,

cooled to room temperature, and poured onto 1000 mL distilled water, stirred for 15 min, and then filtered, followed by washing the filter cake with water and then drying in vacuo at 50° to give 12.8 g (86%) N-(7-acetylamino-4-methoxybenzothiazol-2-yl)benzamide as a light brown solid.

IT **383865-57-4P**, [4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted benzothiazole derivs. by cyclization of N-phenylthiourea or N-phenyl-N'-acylthiourea derivs.)

RN 383865-57-4 CAPLUS

CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



IT **383868-11-9P**, N-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]-2-methylisonicotinamide **383868-12-0P**, N-[4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]benzamide
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted benzothiazole derivs. by cyclization of N-phenylthiourea or N-phenyl-N'-acylthiourea derivs.)

RN 383868-11-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 383868-12-0 CAPLUS

CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:472390 CAPLUS
DOCUMENT NUMBER: 139:53026
TITLE: Preparation of ureidobenzothiazoles as adenosine receptor ligands.
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049741	A1	20030619	WO 2002-EP13761	20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003149036	A1	20030807	US 2002-308338	20021203
US 6727247	B2	20040427		
CA 2469596	AA	20030619	CA 2002-2469596	20021205
BR 2002014825	A	20040914	BR 2002-14825	20021205
EP 1455792	A1	20040915	EP 2002-804578	20021205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516006	T2	20050602	JP 2003-550790	20021205
US 2004229893	A1	20041118	US 2003-691770	20031023
PRIORITY APPLN. INFO.:			EP 2001-129228	A 20011210
			US 2002-308338	A3 20021203
			WO 2002-EP13761	W 20021205

OTHER SOURCE(S): MARPAT 139:53026
GI



I

AB Title compds. [I; R = alkoxy, halo; R1, R2 = H, alkyl, cycloalkyl, tetrahydropyran-4-yl; R1R2N = (substituted) 2-oxa-5-azabicyclo[2.2.1]heptyl, 3-endo-hydroxy-8-azabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.2]octyl, 1-oxo-2,8-diazaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, 8-azaspiro[4.5]decyl, 1-oxa-8-azaspiro[4.5]decyl, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 8-oxa-3-azabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.2.1]octyl, piperazinyl, piperidin-1-yl; X = O, CH2; n = 0-4], were prepared **Thus**, 4-methoxy-7-morpholin-4-ylbenzothiazol-2-ylamine in CH2Cl2 was treated with pyridine and Ph chloroformate and the resulting solution stirred for 45 min at ambient temperature; (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane was added and the mixture stirred at ambient temperature for 15 min and at 40° for 2.5 h. to give (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-ylbenzothiazol-2-yl)amide. This bound to human A2a receptors with pKi = 8.5.

IT **546093-14-5P 546093-15-6P 546093-16-7P**
546093-17-8P 546093-18-9P 546093-19-0P
546093-20-3P 546093-21-4P 546093-22-5P
546093-23-6P 546093-24-7P 546093-25-8P
546093-26-9P 546093-27-0P 546093-28-1P
546093-29-2P 546093-30-5P 546093-31-6P
546093-32-7P 546093-33-8P 546093-34-9P
546093-35-0P 546093-36-1P 546093-37-2P
546093-38-3P 546093-39-4P 546093-40-7P
546093-41-8P 546093-42-9P 546093-49-6P
546093-50-9P 546093-51-0P 546093-52-1P
546093-53-2P 546093-54-3P 546093-55-4P
546093-56-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureidobenzothiazoles as adenosine receptor ligands)

RN 546093-14-5 CAPLUS

CN 2-Oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546093-15-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxamide, 3-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, (3-endo)-rel- (9CI) (CA INDEX NAME)



RN 546093-16-7 CAPLUS
CN 2,8-Diazaspiro[4.5]decane-8-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-methyl-1-oxo- (9CI) (CA INDEX NAME)



RN 546093-17-8 CAPLUS
CN 2,8-Diazaspiro[4.5]decane-8-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-1-oxo- (9CI) (CA INDEX NAME)



RN 546093-18-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(hydroxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 546093-19-0 CAPLUS
CN 3-Azaspiro[5.5]undecane-3-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-20-3 CAPLUS
CN 8-Azaspiro[4.5]decane-8-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-21-4 CAPLUS
CN 2-Azabicyclo[2.2.2]octane-2-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-22-5 CAPLUS
CN 1-Oxa-8-azaspiro[4.5]decane-8-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-23-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(1R)-1-hydroxyethyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546093-24-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(1S)-1-hydroxyethyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546093-25-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(methylsulfonyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 546093-26-9 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-27-0 CAPLUS
CN Urea, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 546093-28-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 546093-29-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 546093-30-5 CAPLUS
CN Urea, N-cyclohexyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 546093-31-6 CAPLUS
CN Urea, N-(cis-4-fluorocyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-32-7 CAPLUS
CN Urea, N-(cis-4-methoxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-33-8 CAPLUS
CN Urea, N-(trans-4-hydroxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-34-9 CAPLUS

CN 1,4-Oxazepine-4(5H)-carboxamide, tetrahydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-35-0 CAPLUS
CN Urea, N-(cis-4-hydroxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-36-1 CAPLUS
CN 2-Oxa-5-azabicyclo[2.2.2]octane-5-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-37-2 CAPLUS
CN Urea, N-(trans-4-methoxycyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 546093-38-3 CAPLUS
CN 2-Azabicyclo[2.2.1]heptane-2-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, (1S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546093-39-4 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 546093-40-7 CAPLUS

CN Urea, N-cycloheptyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 546093-41-8 CAPLUS
CN Urea, N-cyclopentyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 546093-42-9 CAPLUS
CN Urea, N-cyclopentyl-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-49-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-4-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 546093-50-9 CAPLUS
CN 1-Oxa-8-azaspiro[4.5]decane-8-carboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 546093-51-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-chloro-7-(1-piperidinyl)-2-benzothiazolyl]-4-hydroxy-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 546093-52-1 CAPLUS
CN Urea, N-[4-chloro-7-(1-piperidinyl)-2-benzothiazolyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 546093-53-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-chloro-7-(1-piperidinyl)-2-benzothiazolyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 546093-54-3 CAPLUS
CN Urea, N-(4,4-difluorocyclohexyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 546093-55-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane-3-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-1,8,8-trimethyl-, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546093-56-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.1]octane-4-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT **383865-57-4**, 4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylamine **383868-82-4 383869-46-3**, 4-Methoxy-7-piperidin-1-ylbenzothiazol-2-ylamine **546093-47-4**, 4-Chloro-7-(piperidin-1-yl)benzothiazol-2-ylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ureidobenzothiazoles as adenosine receptor ligands)
RN 383865-57-4 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 383868-82-4 CAPLUS
CN Carbamic acid, [[1-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383869-46-3 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 546093-47-4 CAPLUS
CN 2-Benzothiazolamine, 4-chloro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:434364 CAPLUS
DOCUMENT NUMBER: 139:22206
TITLE: Preparation of aroylaminobenzothiazoles as adenosine

receptor antagonists

INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045386	A1	20030605	WO 2002-EP13046	20021121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003134855	A1	20030717	US 2002-295500	20021115
US 6624163	B2	20030923		
CA 2468311	AA	20030605	CA 2002-2468311	20021121
EP 1450797	A1	20040901	EP 2002-790418	20021121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014488	A	20041019	BR 2002-14488	20021121
JP 2005518363	T2	20050623	JP 2003-546888	20021121

PRIORITY APPLN. INFO.: EP 2001-128338 A 20011129
WO 2002-EP13046 W 20021121

OTHER SOURCE(S): MARPAT 139:22206

GI



I

AB Benzothiazoles I [R1 = H, alkyl; R2 = H, alkyl, alkoxyalkyl, cycloalkyl, aminoalkyl; n = 1-3] were prepared for use as A2A receptor antagonists. **Thus**, I [R1 = H, R2 = MeOCH2] was prepared by acylating the amine and had a pKi for human A2A receptor binding of 9.1.

IT **537707-12-3P 537707-15-6P 537707-20-3P**

537707-23-6P 537707-26-9P 537707-29-2P
537707-35-0P 537707-38-3P 537707-41-8P
537707-44-1P 537707-50-9P 537707-53-2P
537707-63-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aroylaminobenzothiazoles as adenosine receptor antagonists)

RN 537707-12-3 CAPLUS
CN Benzamide, 4-[[(methoxyacetyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-15-6 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(3-methoxy-2-oxopropyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 537707-20-3 CAPLUS
CN Benzamide, 4-[[(2-cyclopropyl-2-oxoethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-23-6 CAPLUS
CN Benzamide, 4-[[(2-cyclobutyl-2-oxoethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-26-9 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(2-oxobutyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 537707-29-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(1-oxopropyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 537707-35-0 CAPLUS
CN Benzamide, 4-[[(cyclopropylcarbonyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-38-3 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(2-oxopropyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 537707-41-8 CAPLUS
CN Benzamide, 4-[[(cyclobutylcarbonyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-44-1 CAPLUS
CN Benzamide, 4-[(acetylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-50-9 CAPLUS
CN Benzamide, 4-[[ethyl(1-oxopropyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-53-2 CAPLUS
CN Benzamide, 4-[[[3-(dimethylamino)-2-oxopropyl]amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-63-4 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[[2-oxo-3-(1-pyrrolidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)



IT **383866-22-6 383868-28-8 537707-66-7 537707-71-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aroylaminobenzothiazoles as adenosine receptor antagonists)
RN 383866-22-6 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-28-8 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 537707-66-7 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-71-4 CAPLUS
CN Benzamide, 4-[(ethylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT **537707-56-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aroylaminobenzothiazoles as adenosine receptor antagonists)
RN 537707-56-5 CAPLUS
CN Benzamide, 4-[[(3-chloro-2-oxopropyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT **537707-17-8P 537707-32-7P 537707-47-4P**
537707-59-8P 537707-60-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aroylaminobenzothiazoles as adenosine receptor antagonists)
RN 537707-17-8 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(4-methoxy-2-oxobutyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 537707-32-7 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(3-methoxy-1-oxopropyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 537707-47-4 CAPLUS
CN Benzamide, 4-[[ethyl(methoxyacetyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 537707-59-8 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(2-oxo-1-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 537707-60-1 CAPLUS
CN Benzamide, 4-[[[3-[(2-methoxyethyl)methylamino]-2-oxopropyl]amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:417626 CAPLUS
DOCUMENT NUMBER: 139:6865
TITLE: Nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043636	A1	20030530	WO 2002-EP12562	20021111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003134854	A1	20030717	US 2002-288100	20021105
US 6620811	B2	20030916		
CA 2467552	AA	20030530	CA 2002-2467552	20021111
EP 1448198	A1	20040825	EP 2002-787632	20021111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014245	A	20041214	BR 2002-14245	20021111
PRIORITY APPLN. INFO.:			EP 2001-127312 A	20011119
			WO 2002-EP12562 W	20021111

OTHER SOURCE(S): MARPAT 139:6865
GI



I

AB Title compds. I [R = 2-substituted 4-pyridyl, 4-substituted 3-pyridyl; R1 = Ph, piperidin-1-yl, morpholinyl] were prepared for use as adenosine A2A receptor ligands. **Thus**, 4-methoxy-7-morpholinobenzothiazole-2-amine was acylated with 2-chloroisonicotinoyl chloride and treated with HOCH2CH2OMe to give I [R = 2-(2-methoxyethoxy)pyridin-4-yl, R1 = morpholino] which had a pKi for the human A2A receptor of 8.50.

IT **535924-18-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)

RN 535924-18-6 CAPLUS
CN Butanoic acid, 4-[[[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-2-pyridinyl]methyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **533932-09-1P 535923-58-1P 535923-60-5P**
535923-61-6P 535923-62-7P 535923-64-9P
535923-66-1P 535923-69-4P 535923-71-8P
535923-73-0P 535923-74-1P 535923-80-9P
535923-82-1P 535923-87-6P 535923-91-2P
535923-96-7P 535924-00-6P 535924-03-9P
535924-07-3P 535924-10-8P 535924-12-0P
535924-14-2P 535924-21-1P 535924-26-6P
535924-27-7P 535924-29-9P 535924-30-2P
535924-31-3P 535924-32-4P 535924-33-5P
535924-37-9P 535924-38-0P 535924-40-4P
535924-42-6P 535924-43-7P 535924-44-8P
535924-45-9P 535924-46-0P 535924-47-1P
535924-49-3P 535924-50-6P 535924-51-7P
535924-52-8P 535924-53-9P 535924-54-0P
535924-56-2P 535924-57-3P 535924-59-5P
535924-60-8P 535924-61-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)

RN 533932-09-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-methoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-58-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-(2-methoxyethoxy)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-60-5 CAPLUS
CN 4-Pyridinecarboxamide, 2-ethoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-61-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 535923-62-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 535923-64-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 535923-66-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 535923-69-4 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 535923-71-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[2-(acetylamino)ethyl]amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-73-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[2-(2-oxo-1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 535923-74-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 535923-80-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-cyclohexyl-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-82-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-(1-azetidinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-87-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535923-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-methoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-96-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 535924-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 535924-03-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-07-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(butylmethylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-10-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 535924-12-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 535924-14-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 535924-21-1 CAPLUS
CN Carbamic acid, [[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-2-pyridinyl]methyl]methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 535924-26-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 535924-27-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-2-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 535924-29-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-(1,1-dioxido-4-thiomorpholinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-30-2 CAPLUS
CN 4-Pyridinecarboxamide, 2-(3-hydroxy-1-azetidinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-31-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-(3-methoxy-1-azetidinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-32-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-(3-ethoxy-1-azetidinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-33-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 535924-37-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 535924-38-0 CAPLUS
CN 4-Pyridinecarboxamide, 2-(ethylthio)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-40-4 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 535924-42-6 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclopentyloxy)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-43-7 CAPLUS
CN 4-Pyridinecarboxamide, 2-[2-(dimethylamino)ethoxy]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-44-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 535924-45-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[2-(dimethylamino)ethyl]amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-46-0 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclopentylamino)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-47-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclobutylamino)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-49-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-[2-(acetylamino)ethoxy]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-50-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(propylamino)- (9CI) (CA INDEX NAME)



RN 535924-51-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(methylpropylamino)- (9CI) (CA INDEX NAME)



RN 535924-52-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclohexylmethylamino)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-53-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 535924-54-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[methyl(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 535924-56-2 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[2-(dimethylamino)ethyl]methylamino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-57-3 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 535924-59-5 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(4-hydroxy-1-piperidinyl)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-60-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(ethylthio)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-61-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(2-ethoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT **383865-57-4 383869-46-3 535924-71-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)
RN 383865-57-4 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 383869-46-3 CAPLUS
CN 2-Benzothiazolamine, 4-methoxy-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 535924-71-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(methylamino)- (9CI) (CA INDEX NAME)



IT **383869-82-7P 535924-24-4P 535924-28-8P**
535924-67-5P 535924-68-6P 535924-70-0P
535924-72-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)
RN 383869-82-7 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-24-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-28-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-(chloromethyl)-N-[4-methoxy-7-(1-piperidinyl)-2-

benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-67-5 CAPLUS
CN 4-Pyridinecarboxamide, 2-bromo-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-68-6 CAPLUS
CN 4-Pyridinecarboxamide, 2-(1-cyclohexen-1-yl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-70-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-72-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)



IT **535924-20-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)
RN 535924-20-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(2-oxo-1-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



IT **535923-59-2P 535923-63-8P 535923-65-0P**
535923-67-2P 535923-68-3P 535923-70-7P
535923-72-9P 535923-75-2P 535923-76-3P

535923-77-4P 535923-78-5P 535923-79-6P
535923-81-0P 535923-83-2P 535923-84-3P
535923-85-4P 535923-86-5P 535923-88-7P
535923-89-8P 535923-90-1P 535923-92-3P
535923-93-4P 535923-94-5P 535923-95-6P
535923-97-8P 535923-98-9P 535923-99-0P
535924-01-7P 535924-02-8P 535924-04-0P
535924-05-1P 535924-06-2P 535924-08-4P
535924-09-5P 535924-11-9P 535924-13-1P
535924-15-3P 535924-16-4P 535924-17-5P
535924-19-7P 535924-22-2P 535924-23-3P
535924-34-6P 535924-36-8P 535924-39-1P
535924-41-5P 535924-48-2P 535924-55-1P
535924-62-0P 535924-63-1P 535924-64-2P
535924-65-3P 535924-66-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)

RN 535923-59-2 CAPLUS
CN 4-Pyridinecarboxamide, 2-[2-(2-methoxyethoxy)ethoxy]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-63-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[methyl[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 535923-65-0 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(2-methoxyethyl)methylamino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-67-2 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(2-methoxyethyl)amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-68-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-(4-acetyl-1-piperazinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-70-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[methyl[2-(1-piperidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 535923-72-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 535923-75-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[[2-(1-piperidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 535923-76-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-[ethyl[2-(2-pyridinyl)ethyl]amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-77-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-[ethyl(2-methoxyethyl)amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-78-5 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(2-ethoxyethyl)amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-79-6 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535923-81-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(4-methyl-3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 535923-83-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(4-methoxy-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 535923-84-3 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(3-methoxy-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 535923-85-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-(4-ethyl-3-oxo-1-piperazinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-86-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 535923-88-7 CAPLUS
CN 4-Pyridinecarboxamide, 2-(3-hydroxy-1-piperidinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-89-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-(4-hydroxy-1-piperidinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-ethoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-acetyl-1-piperazinyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-methoxyethoxy)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-94-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 535923-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 535923-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(2-methoxyethyl)amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535923-98-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-propoxy- (9CI) (CA INDEX NAME)



RN 535923-99-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-butoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(cyclohexyloxy)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-02-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-04-0 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[ethyl(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-05-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(2-ethoxyethyl)ethylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-06-2 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(2-ethoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-08-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(butylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-09-5 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(diethylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-11-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 535924-13-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(4-methoxy-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 535924-15-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(ethylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-16-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(cyclopropylmethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-17-5 CAPLUS
CN 4-Pyridinecarboxamide, 2-(1-azetidinylmethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-19-7 CAPLUS
CN Butanoic acid, 4-[[[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-2-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 535924-22-2 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(2-methoxyethoxy)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-23-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-(methoxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-34-6 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclohexyloxy)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-36-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclohexylamino)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-39-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-(butylthio)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-41-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-(2-methylpropoxy)- (9CI) (CA INDEX NAME)



RN 535924-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[ethyl(2-methoxyethyl)amino]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-55-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 535924-62-0 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535924-63-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(3S)-3-(methoxymethyl)-1-pyrrolidinyl]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535924-64-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(2-methyl-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 535924-65-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-[(acetylmethylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 535924-66-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-[[(methoxyacetyl)methylamino]methyl]-N-[4-methoxy-

7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:417624 CAPLUS
DOCUMENT NUMBER: 139:6879
TITLE: Preparation of N-[7-(morpholin-4-yl)benzothiazol-2-yl] 2-oxo-1,2-dihydropyridine-4-carboxamides as adenosine receptor ligands
INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043634	A1	20030530	WO 2002-EP12543	20021109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6599901	B1	20030729	US 2002-288531	20021105
CA 2467551	AA	20030530	CA 2002-2467551	20021109
EP 1448196	A1	20040825	EP 2002-803360	20021109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014221	A	20040921	BR 2002-14221	20021109
JP 2005515980	T2	20050602	JP 2003-545315	20021109
PRIORITY APPLN. INFO.:			EP 2001-127313 A	20011119
			WO 2002-EP12543 W	20021109

OTHER SOURCE(S): MARPAT 139:6879
GI



I

AB The title compds. [I; R = Ph, pyridin-2-yl, CO2(alkyl), CO(alkyl), CO(morpholinyl), CON(R1)2, (CH2)nN(R1)2 or (CH2)nO(alkyl); R1 = H, alkyl] which have a good affinity to the A2A receptor and therefore they may be used in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or against asthma, allergic responses, hypoxia, ischemia, seizure and substance abuse, were prepared and formulated. **Thus**, reacting 2-methoxy-N-[4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl]isonicotinamide with PhCH2Br in the presence of NaI in MeCN afforded 32% I [R = Ph] which showed pKi of 8.67 against human adenosine A2A receptor binding. Furthermore, compds. of I may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents for disorders such as coronary artery disease and heart failure.

IT **533932-03-5P 533932-04-6P 533932-05-7P**
533932-06-8P 533932-07-9P 533932-08-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[7-(morpholin-4-yl)benzothiazol-2-yl] 2-oxo-1,2-dihydropyridine-4-carboxamides as adenosine receptor ligands)

RN 533932-03-5 CAPLUS

CN 4-Pyridinecarboxamide, 1,2-dihydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 533932-04-6 CAPLUS
CN 1(2H)-Pyridineacetic acid, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 533932-05-7 CAPLUS
CN 4-Pyridinecarboxamide, 1,2-dihydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-oxo-1-(2-oxobutyl)- (9CI) (CA INDEX NAME)



RN 533932-06-8 CAPLUS
CN 4-Pyridinecarboxamide, 1,2-dihydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-oxo-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 533932-07-9 CAPLUS
CN 4-Pyridinecarboxamide, 1,2-dihydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 533932-08-0 CAPLUS
CN 1(2H)-Pyridineacetamide, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



IT **533932-09-1 533932-10-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[7-(morpholin-4-yl)benzothiazol-2-yl] 2-oxo-1,2-dihydropyridine-4-carboxamides as adenosine receptor ligands)
RN 533932-09-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-methoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 533932-10-4 CAPLUS
CN 4-Pyridinecarboxamide, 1,2-dihydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:935384 CAPLUS
DOCUMENT NUMBER: 136:69803
TITLE: Preparation of N-benzothiazol-2-yl amides having affinity toward the A2A adenosine receptor
INVENTOR(S): Alanine, Alexander; Flohr, Alexander; Miller, Aubry Kern; Norcross, Roger David; Riemer, Claus
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097786	A2	20011227	WO 2001-EP6506	20010608
WO 2001097786	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413086	AA	20011227	CA 2001-2413086	20010608
EP 1303272	A2	20030423	EP 2001-960284	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012395	A	20030708	BR 2001-12395	20010608
JP 2003535887	T2	20031202	JP 2002-503263	20010608
RU 2251419	C2	20050510	RU 2003-100518	20010608
NZ 522928	A	20050527	NZ 2001-522928	20010608
US 2002045615	A1	20020418	US 2001-881252	20010614
US 6521754	B2	20030218		
ZA 2002009730	A	20040301	ZA 2002-9730	20021129
US 2003125318	A1	20030703	US 2002-310508	20021205
US 6835732	B2	20041228		
NO 2002005978	A	20021212	NO 2002-5978	20021212
US 2003176695	A1	20030918	US 2002-322272	20021218

US 2005026906 A1 20050203 US 2004-930361 20040830
PRIORITY APPLN. INFO.: EP 2000-113219 A 20000621
WO 2001-EP6506 W 20010608
US 2001-881252 A3 20010614
US 2002-322272 A3 20021218
OTHER SOURCE(S): MARPAT 136:69803
GI



I

AB The title compds. [I; R1 = H, alkyl, alkoxy, etc.; R2, R3 = H, halo, alkyl, alkoxy; R4 = H, alkyl, alkenyl, etc.; R = (un)substituted Ph, (CH2)n(5-6 membered (non)aromatic heterocyclyl, (CH2)n+1Ph, etc.; n = 0-4; X = O, S, H2)], useful for the treatment of diseases related to the adenosine receptor, were prepared **Thus**, reacting 2-amino-4-methoxy-7-phenylbenzothiazole with benzoyl chloride in pyridine afforded 69% I [R1 = OMe; R2, R3 = H; R4 = Ph; R = Ph; X = O]. Biol. data for compds. I were given.

IT **383866-22-6P**, 4-Chloromethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-28-8P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((methylamino)methyl)benzamide **383868-82-4P 383868-97-1P 383869-76-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383866-22-6 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-28-8 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 383868-82-4 CAPLUS
CN Carbamic acid, [[1-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383868-97-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(hydroxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-76-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-methyl- (9CI) (CA INDEX NAME)



IT **383865-56-3P** **383866-23-7P**, 4-(4-Hydroxypiperidin-1-ylmethyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383866-24-8P**, 4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383866-25-9P**, 4-[[N-(2-Hydroxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383866-28-2P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-(piperazin-1-ylmethyl)benzamide **383866-31-7P**, Thiomorpholine-4-carboxylic acid (4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)amide **383866-32-8P**, Morpholine-4-carboxylic acid, (4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)amide **383866-33-9P**, 3-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-1-methyl-1-((6-methylpyridin-3-yl)methyl)urea **383867-05-8P**, (4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)carbamic acid methyl ester **383868-01-7P**, N-[2-[4-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)phenyl]ethyl]-N-methylcarbamic acid tert-butyl ester **383868-03-9P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-(1,1,2,2-tetrafluoroethoxy)benzamide **383868-05-1P**, 4-[N-(2-Methoxyethyl)-N-methylsulfamoyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-06-2P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-trifluoromethylbenzamide **383868-07-3P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-trifluoromethoxybenzamide **383868-08-4P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-trifluoromethoxybenzamide **383868-09-5P**, 4-Ethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-10-8P**, 4-Fluoro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-11-9P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-2-methylisonicotinamide **383868-12-0P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-13-1P**, 4-Chloro-3-[[N-ethyl-N-(2-methoxyethyl)amino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-14-2P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-((N-methylamino)methyl)benzamide **383868-15-3P**, 4-Chloro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-((N-methylamino)methyl)benzamide **383868-16-4P**, 4-Chloro-3-[[N-(2-methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-17-5P**, 4-Chloro-3-[N-(2-methoxyethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-18-6P**, 4-Chloro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-(pyrrolidin-1-ylmethyl)benzamide **383868-19-7P**, 1-[4-(4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)benzyl]pyridinium chloride **383868-21-1P**, 3-Fluoro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-(pyrrolidin-1-ylmethyl)benzamide **383868-22-2P**, 3-[N-(2-Methoxy-

ethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-23-3P**, 3-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-24-4P**, 1-[4-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)benzyl]pyridinium chloride **383868-25-5P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-(pyrrolidin-1-ylmethyl)benzamide **383868-26-6P**, 4-[N-(2-Ethoxyethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-benzamide **383868-27-7P**, (R)-N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((3-methoxypyrrolidin-1-yl)methyl)benzamide **383868-29-9P**, (S)-N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((3-methoxypyrrolidin-1-yl)methyl)benzamide **383868-30-2P**, 4-(Azetidin-1-ylmethyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-31-3P**, 4-[1-(2-Methoxyethylamino)ethyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-32-4P**, 4-[1-[N-(2-Methoxyethyl)-N-methylamino]ethyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-33-5P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-(1-(pyrrolidin-1-yl)ethyl)benzamide **383868-34-6P**, 4-(2-(Dimethylamino)ethylsulfanylmethyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-35-7P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-[[N-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)amino]methyl]benzamide **383868-37-9P**, 4-[[N-Ethyl-N-(2-methoxy-ethyl)amino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-38-0P**, 4-[[N-(2-Ethoxyethyl)-N-ethylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-40-4P**, 3-Fluoro-4-[[N-(2-methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-41-5P**, 4-[[N,N-Bis(2-ethoxyethyl)amino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-42-6P**, 4-[[N-(2-Ethoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-43-7P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((4-methoxypiperidin-1-yl)methyl)benzamide **383868-44-8P**, 4-(Diethylamino)methyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-45-9P**, 4-[N-(2-Methoxyethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-46-0P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((2-methylimidazol-1-yl)methyl)benzamide **383868-47-1P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide **383868-48-2P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((pyrrolidin-1-yl)methyl)benzamide **383868-49-3P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((morpholin-4-yl)methyl)benzamide **383868-50-6P**, N-(4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-[[N-(2-methoxyethyl)-N-methylamino]methyl]benzamide **383868-52-8P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-[[N-methyl-N-(3,3,3-trifluoropropyl)amino]methyl]benzamide hydrochloride **383868-53-9P**, 4-((2-Methoxyethoxy)methyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-54-0P**, 4-Methoxymethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-66-4P**, N-(4-Hydroxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383868-69-7P 383868-70-0P**, 4-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester **383868-71-1P 383868-72-2P**, Piperidine-4-carboxylic acid (4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)amide **383868-73-3P 383868-75-5P 383868-76-6P**

383868-78-8P 383868-79-9P 383868-80-2P
383868-81-3P 383868-83-5P 383868-84-6P
383868-85-7P, N-(2-Methoxyethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methylurea **383868-87-9P**
383868-89-1P 383868-91-5P 383868-93-7P
383868-95-9P 383869-00-9P 383869-01-0P
383869-02-1P 383869-03-2P 383869-05-4P
383869-07-6P 383869-09-8P 383869-11-2P
383869-13-4P 383869-15-6P 383869-17-8P, N'-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-(4-methoxyphenyl)-N-methylurea **383869-19-0P 383869-21-4P**
383869-23-6P, N'-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methyl-N-phenylurea **383869-25-8P 383869-27-0P**
383869-29-2P 383869-31-6P 383869-34-9P
383869-37-2P 383869-39-4P, (4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)carbamic acid 2-methoxyethyl ester
383869-42-9P, N-[4-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)benzyl]-N-methylcarbamic acid methyl ester
383869-44-1P 383869-48-5P, N-(4-Ethoxy-7-(piperidin-1-yl)benzothiazol-2-yl)-4-fluorobenzamide **383869-54-3P**, 4-Fluoro-N-(4-isopropoxy-7-(piperidin-1-yl)benzothiazol-2-yl)benzamide
383869-78-1P, (4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea
383869-80-5P, (4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)carbamic acid phenyl ester **383869-82-7P**, 2-Chloro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)isonicotinamide
383869-84-9P, 2-Iodo-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-6-methylisonicotinamide **383869-86-1P**, N-Benzyl-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methylurea **383869-88-3P**, N'-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methyl-N-phenethylurea **383869-90-7P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-2-phenylacetamide **383869-92-9P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)propionamide
383869-94-1P, 2-Methoxy-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)acetamide **383869-96-3P**, Pentanoic acid (4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)amide **383869-98-5P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)isobutyramide
383870-00-6P, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-phenylpropionamide **383870-02-8P**, N-Benzyl-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea **383870-05-1P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N'-phenethylurea
383870-07-3P, N-(2-Methoxyethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea **383870-09-5P**, N-(2-Dimethylaminoethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-N-methylurea
383870-11-9P, N-(2-Dimethylaminoethyl)-N'-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)urea **383870-13-1P**, 4-(Dimethylamino)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)butyramide
383871-39-4P 383871-76-9P, 4-[((2-(Dimethylamino)ethyl)sulfanyl)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-benzamide **383911-03-3P**
383911-05-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383865-56-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383866-23-7 CAPLUS
CN Benzamide, 4-[(4-hydroxy-1-piperidinyl)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-24-8 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-25-9 CAPLUS
CN Benzamide, 4-[[(2-hydroxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-28-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)



RN 383866-31-7 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-32-8 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-33-9 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-[(6-methyl-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 383867-05-8 CAPLUS
CN Carbamic acid, [4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383868-01-7 CAPLUS
CN Carbamic acid, [2-[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383868-03-9 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)



RN 383868-05-1 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]sulfonyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-06-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 383868-07-3 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 383868-08-4 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 383868-09-5 CAPLUS
CN Benzamide, 4-ethyl-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-10-8 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-11-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 383868-12-0 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-13-1 CAPLUS
CN Benzamide, 4-chloro-3-[[ethyl(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-14-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 383868-15-3 CAPLUS
CN Benzamide, 4-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 383868-16-4 CAPLUS
CN Benzamide, 4-chloro-3-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-17-5 CAPLUS
CN Benzamide, 4-chloro-3-[[(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-18-6 CAPLUS
CN Benzamide, 4-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-19-7 CAPLUS
CN Pyridinium, 1-[[4-[[[7-(4-morpholinyl)-4-(phenylmethoxy)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RN 383868-21-1 CAPLUS
CN Benzamide, 3-fluoro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-22-2 CAPLUS
CN Benzamide, 3-[[(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-23-3 CAPLUS
CN Benzamide, 3-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-24-4 CAPLUS
CN Pyridinium, 1-[[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RN 383868-25-5 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-26-6 CAPLUS
CN Benzamide, 4-[[(2-ethoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-27-7 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(3R)-3-methoxy-1-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383868-29-9 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(3S)-3-methoxy-1-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383868-30-2 CAPLUS
CN Benzamide, 4-(1-azetidinylmethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-31-3 CAPLUS
CN Benzamide, 4-[1-[(2-methoxyethyl)amino]ethyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-32-4 CAPLUS
CN Benzamide, 4-[1-[(2-methoxyethyl)methylamino]ethyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-33-5 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[1-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 383868-34-6 CAPLUS
CN Benzamide, 4-[(dimethylamino)(ethylthio)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-35-7 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[methyl(4,4,4-trifluoro-3-hydroxybutyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 383868-37-9 CAPLUS
CN Benzamide, 4-[[ethyl(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-38-0 CAPLUS
CN Benzamide, 4-[[(2-ethoxyethyl)ethylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-40-4 CAPLUS
CN Benzamide, 3-fluoro-4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-41-5 CAPLUS
CN Benzamide, 4-[[bis(2-ethoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-42-6 CAPLUS
CN Benzamide, 4-[[(2-ethoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-43-7 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(4-methoxy-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-44-8 CAPLUS
CN Benzamide, 4-[(diethylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-45-9 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-46-0 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(2-methyl-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-47-1 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-48-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-49-3 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-50-6 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[7-(4-morpholinyl)-4-(phenylmethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-52-8 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[methyl(3,3,3-trifluoropropyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383868-53-9 CAPLUS
CN Benzamide, 4-[(2-methoxyethoxy)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-54-0 CAPLUS
CN Benzamide, 4-(methoxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-66-4 CAPLUS
CN Benzamide, N-[4-hydroxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-69-7 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-70-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383868-71-1 CAPLUS
CN 4-Piperidinecarboxamide, 1-acetyl-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-72-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-73-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[(4-fluorophenyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-75-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(hydroxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 383868-76-6 CAPLUS
CN Carbamic acid, [[1-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-4-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383868-78-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-ethyl-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-79-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(2-oxo-1-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-80-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-methoxyethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-81-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyanomethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-83-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-[2-(4-chlorophenyl)tetrahydro-2-furanyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-84-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-hydroxyethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-85-7 CAPLUS
CN Urea, N-(2-methoxyethyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 383868-87-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(methoxyacetyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-89-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 383868-91-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 383868-93-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopropyl-4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-95-9 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 383869-00-9 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-01-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383869-02-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 383869-03-2 CAPLUS
CN 1-Piperidinecarboxamide, 3-(hydroxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-05-4 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-07-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383869-09-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 383869-11-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 383869-13-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 383869-15-6 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-17-8 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 383869-19-0 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane-8-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-21-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, 3,4-dihydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-23-6 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 383869-25-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-27-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-methoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-29-2 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 383869-31-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(methylsulfonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 383869-34-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-37-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(aminomethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-39-4 CAPLUS
CN Carbamic acid, [4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 383869-42-9 CAPLUS
CN Carbamic acid, [[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 383869-44-1 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-, 1-oxide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383869-48-5 CAPLUS
CN Benzamide, N-[4-ethoxy-7-(1-piperidinyl)-2-benzothiazolyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 383869-54-3 CAPLUS
CN Benzamide, 4-fluoro-N-[4-(1-methylethoxy)-7-(1-piperidinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-78-1 CAPLUS
CN Urea, [4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-80-5 CAPLUS
CN Carbamic acid, [4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 383869-82-7 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-84-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-iodo-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 383869-86-1 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 383869-88-3 CAPLUS
CN Urea, N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 383869-90-7 CAPLUS
CN Benzeneacetamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-92-9 CAPLUS
CN Propanamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-94-1 CAPLUS
CN Acetamide, 2-methoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-96-3 CAPLUS
CN Pentanamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-98-5 CAPLUS
CN Propanamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 383870-00-6 CAPLUS
CN Benzenepropanamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-
(9CI) (CA INDEX NAME)



RN 383870-02-8 CAPLUS
CN Urea, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N'-(phenylmethyl)-
(9CI) (CA INDEX NAME)



RN 383870-05-1 CAPLUS
CN Urea, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N'-(2-phenylethyl)-
(9CI) (CA INDEX NAME)



RN 383870-07-3 CAPLUS
CN Urea, N-(2-methoxyethyl)-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383870-09-5 CAPLUS
CN Urea, N-[2-(dimethylamino)ethyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 383870-11-9 CAPLUS
CN Urea, N-[2-(dimethylamino)ethyl]-N'-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383870-13-1 CAPLUS
CN Butanamide, 4-(dimethylamino)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-39-4 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 383871-76-9 CAPLUS
CN Benzamide, 4-[[[2-(dimethylamino)ethyl]thio]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383911-03-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, hexahydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

CM 1

CRN 383911-02-2
CMF C22 H30 N4 O3 S



RN 383911-05-5 CAPLUS
CN 1(2H)-Quinolinecarboxamide, hexahydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

CM 1

CRN 383911-04-4
CMF C22 H30 N4 O3 S



IT **383866-26-0**, 3,4-Dimethoxybenzoic acid 2-[N-[4-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)benzyl]-N-methylamino]ethyl ester **383869-46-3**, 4-Methoxy-7-piperidin-1-yl-benzothiazol-2-ylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383866-26-0 CAPLUS

CN Benzoic acid, 3,4-dimethoxy-, 2-[[[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]methylamino]ethyl ester (9CI) (CA INDEX NAME)



RN 383869-46-3 CAPLUS

CN 2-Benzothiazolamine, 4-methoxy-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



IT **383865-57-4P**, 2-Amino-4-methoxy-7-(morpholin-4-yl)benzothiazole **383868-20-0P**, 4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-ylamine **383868-51-7P**, N-(4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-chloromethylbenzamide **383870-98-2P**, 4-Chloromethyl-N-(4-hydroxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383871-01-0P**, 4-(1-Bromoethyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383871-03-2P**, 3-Chloromethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383871-04-3P**, 4-Chloromethyl-3-fluoro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-benzamide **383871-06-5P**, 4-Chloro-3-chloromethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383865-57-4 CAPLUS

CN 2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 383868-20-0 CAPLUS
CN 2-Benzothiazolamine, 7-(4-morpholinyl)-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 383868-51-7 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[7-(4-morpholinyl)-4-(phenylmethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383870-98-2 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-hydroxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-01-0 CAPLUS
CN Benzamide, 4-(1-bromoethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-03-2 CAPLUS
CN Benzamide, 3-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-04-3 CAPLUS
CN Benzamide, 4-(chloromethyl)-3-fluoro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-06-5 CAPLUS
CN Benzamide, 4-chloro-3-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	72.40	574.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.22	-12.41

STN INTERNATIONAL LOGOFF AT 09:13:07 ON 19 JUL 2005